Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.40 |
| ▸ | CPB1 | P15086 | 4/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601990 | 0.87 | CYP1A2 (0.38) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL3839522 | 0.80 | SIRT2 (0.49) | CYP1A2CPB2CPB1ALPIPKM | |
| SCHEMBL21690129 | 0.80 | SIRT2 (0.49) | CYP1A2CPB2CPB1ALPIPKM | |
| SCHEMBL6773700 | 0.80 | SIRT2 (0.49) | CYP1A2CPB2CPB1ALPIPKM | |
| SCHEMBL28977981 | 0.80 | SLC7A5 (0.44) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL52215 | 0.80 | CYP2C9 (0.47) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL28977985 | 0.80 | SLC7A5 (0.44) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL52216 | 0.80 | CYP2C9 (0.47) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL7001068 | 0.80 | SLC7A5 (0.44) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL4437439 | 0.80 | SLC7A5 (0.44) | CYP1A2CPB2CPB1GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573895-A | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2017-04-19 | — | — | CN | claimed |
| CN-106573895-A | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2017-04-19 | — | — | CN | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | CYP1A2 537/4885CPB2 97/4885CPB1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.